Harold Thomas, MD
Neurology · Birmingham, ALNPI 1194818641
Payments from drug & device makers
Across 415 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$2K
- EMD Serono, Inc.$1K
- Novartis$1K
- AbbVie$757
- Amgen$633
- CSL Behring$621
- plus $3K from 31 others
What the payments were for
- Food & beverage$9,541100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 92 | $1,669 |
| EMD Serono, Inc. | 33 | $1,231 |
| Novartis | 18 | $1,184 |
| AbbVie(2 entities) | 57 | $757 |
| Amgen(2 entities) | 21 | $633 |
| CSL Behring | 10 | $621 |
| Argenx US, Inc. | 31 | $507 |
| Acadia Pharmaceuticals Inc | 25 | $376 |
| MDD US Operations, LLC | 22 | $374 |
| Johnson & Johnson(2 entities) | 8 | $287 |
| Neurelis, Inc. | 2 | $241 |
| Teva Pharmaceuticals USA, Inc. | 12 | $237 |
| AstraZeneca(2 entities) | 13 | $226 |
| SK Life Science, Inc. | 7 | $124 |
| Sanofi | 7 | $115 |
| Biohaven Pharmaceuticals, Inc. | 5 | $97 |
| Pfizer | 6 | $96 |
| Lundbeck LLC | 5 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $92 |
| Lilly USA, LLC | 6 | $91 |
| ANI Pharmaceuticals, Inc. | 3 | $79 |
| Avion Pharmaceuticals | 3 | $44 |
| Kyowa Kirin, Inc. | 3 | $40 |
| Bristol Myers Squibb | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Livanova USA, Inc. | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| UCB, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| TG Therapeutics, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,559 in reported general payments places this provider in the 60th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 13 | $641,889 |
| EnspryngSatralizumab-Mwge | 12 | $231,510 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 39 | $135,921 |
| Plegridy PenPeginterferon Beta-1a | 14 | $110,399 |
| Kesimpta PenOfatumumab | 12 | $108,177 |
| NuplazidPimavanserin Tartrate | 16 | $70,659 |
| Aimovig AutoinjectorErenumab-Aooe | 62 | $46,966 |
| UbrelvyUbrogepant | 35 | $39,015 |
| Keppra XrLevetiracetam | 19 | $37,613 |
| Lamictal XrLamotrigine | 15 | $36,035 |
| BriviactBrivaracetam | 21 | $29,200 |
| Nurtec OdtRimegepant Sulfate | 22 | $23,406 |
| Lacosamide | 122 | $20,175 |
| AptiomEslicarbazepine Acetate | 11 | $16,272 |
| HorizantGabapentin Enacarbil | 12 | $11,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $226 | $641,88913 claims |
| Acadia Pharmaceuticals IncNuplazid | $376 | $70,65916 claims |
| AbbVieUbrelvy | $757 | $39,01535 claims |
| UCB, Inc.Briviact | $21 | $29,20021 claims |
| PfizerNurtec Odt | $96 | $23,40622 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $17 | $16,27211 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $25 | $11,73712 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $27 | $3,40629 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $1,085125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Emily RiserBirmingham$7.1M
- Louis NaborsBirmingham$3.2M
- Khurram BashirBirmingham$2.8M
- David GeldmacherBirmingham$2.6M
- Victor SungBirmingham$2M
- Mina LobbousBirmingham$1.8M
- Diane CounceBirmingham$1.4M
- Marissa Natelson LoveBirmingham$792K
- David StandaertBirmingham$787K
- Marissa DeanBirmingham$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.